FDA Approves Subcutaneous Leqembi Starting Dose for Alzheimer's Treatment

Why it matters locally: The FDA's approval of a subcutaneous starting dose for Leqembi could significantly impact Californians living with early Alzheimer's disease, offering a more accessible treatment option for a state with a large and aging population.

NEW YORK – The U.S. Food and Drug Administration (FDA) today, July 13, 2026, approved a weekly subcutaneous starting dose for Leqembi. Leqembi is a medication for individuals with early Alzheimer's disease. Dr. Howard Fillit, co-founder and chief science officer of the Alzheimer's Drug Discovery Foundation (ADDF), discussed the FDA's decision. "The FDA approval of a subcutaneous starting dose for Leqembi provides an additional administration method for patients," Dr. Fillit stated. He added that the ADDF previously supported the development of Leqembi through research funding for its underlying amyloid-beta directed mechanism. ADDF stated that the new subcutaneous starting dose offers an alternative to the previously approved intravenous administration. They drew parallels to subcutaneous administration methods used for therapies addressing diabetes and GLP-1 weight loss. Dr. Fillit also commented on the future direction of Alzheimer's treatment. "This approval contributes to the evolving landscape of Alzheimer's care," Dr. Fillit said. He noted that the ADDF continues to support the development of various therapeutic approaches for Alzheimer's disease. The ADDF has invested over $275 million in drug discovery programs. The organization supports research into various therapeutic targets for Alzheimer's and related dementias.